News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cardiogenesis Corporation (CGCP) to Report 2010 Fourth Quarter and Full-Year Results on March 9th


2/23/2011 6:47:33 AM

IRVINE, Calif., Feb, 23, 2011 /PRNewswire/ -- Cardiogenesis Corporation (Pink Sheets: CGCP) announced that the company will release results for its fourth quarter and full-year ended December 31, 2010 on Wednesday, March 9, 2011. The company added that Paul J. McCormick, its Executive Chairman, and William R. Abbott, its Senior Vice President and Chief Financial Officer, will host an investor conference call that day at 5:00 p.m. Eastern time (2:00 p.m. Pacific time) to review the company's financial results and business outlook.

The call is open to all interested investors through a live audio broadcast via the Internet at www.cardiogenesis.com. The call also will be available to investors and analysts by dialing (800) 299-7928 within the U.S. and Canada and (617) 614-3926 from abroad. The passcode is 10201520.

The webcast will be archived on the company's web site and will be available for playback for seven days beginning shortly after the live webcast. A telephonic playback of the conference call will be available beginning at 8:00 p.m. Eastern time on Wednesday, March 9, 2011 and continue through 8:00 p.m. Eastern time on Wednesday, March 16, 2011. The replay can be accessed by calling (888) 286-8010 within the U.S. and Canada and (617) 801-6888 from abroad. The replay passcode is 95647567.

About Cardiogenesis Corporation

Cardiogenesis is a medical device company specializing in the treatment of cardiovascular disease and is a leader in devices that stimulate cardiac angiogenesis. The company's market leading Holmium:YAG laser system and disposable fiber-optic accessories are used to perform a FDA-cleared surgical procedure known as Transmyocardial Revascularization (TMR) to treat patients suffering from angina. Surgical products and accessories for the Cardiogenesis TMR procedure, which are marketed in the U.S. and around the world, have been shown to reduce angina and improve the quality of life in patients with coronary artery disease.

For more information on the company and its products, please visit the Cardiogenesis company website at www.cardiogenesis.com.

SOURCE Cardiogenesis Corporation


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES